{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:14:01Z","timestamp":1778674441303,"version":"3.51.4"},"reference-count":40,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012737","name":"Department of Health and Human Service","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Natriuretic peptide concentrations are inversely associated with risk of diabetes mellitus and may be protective from metabolic dysfunction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We studied associations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) with incident diabetes, metabolic syndrome (MetS), and MetS components.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 2899 participants with baseline (2003-2007) and follow-up (2013-2016) examinations and baseline NT-proBNP measurement in the REasons for Geographic And Racial Differences in Stroke study. Logistic regression models were fitted to incident MetS, MetS components, and diabetes; covariates included demographics, risk and laboratory factors. Incident diabetes was defined as fasting glucose \u2265126\u2005mg\/dL, random glucose \u2265200\u2005mg\/dL, or use of insulin or hypoglycemic drugs at follow-up but not baseline. Incident MetS was defined as participants with \u22653 harmonized criteria at follow-up and &amp;lt;3 at baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 310 participants (2364 at risk) developed diabetes and 361 (2059 at risk) developed MetS over a mean 9.4 years of follow-up. NT-proBNP was inversely associated with odds of incident diabetes (fully adjusted OR per SD higher log NT-proBNP 0.80, 95% CI 0.69-0.93) and MetS in the highest vs lowest quartile only (fully adjusted OR 0.59, 95% CI 0.37-0.92); the linear association with incident MetS was not statistically significant. NT-proBNP was inversely associated with incident dysglycemia in all models (fully adjusted OR per SD log NT-proBNP 0.65, 95% CI 0.53-0.79), but not with other MetS components. Effect modification by sex, race, age, or body mass index was not observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>NT-proBNP was inversely associated with odds of diabetes, MetS, and the MetS dysglycemia component. The metabolic implications of B-type natriuretic peptides appear important for glycemic homeostasis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae301","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T12:46:36Z","timestamp":1714826796000},"page":"e1185-e1193","source":"Crossref","is-referenced-by-count":1,"title":["N-terminal Pro-B-Type Natriuretic Peptide and Risk for Diabetes Mellitus and Metabolic Syndrome"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-1024","authenticated-orcid":false,"given":"Charles D","family":"Nicoli","sequence":"first","affiliation":[{"name":"Department of Medicine, Walter Reed National Military Medical Center , Bethesda, MD 20889 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8614-7190","authenticated-orcid":false,"given":"D Leann","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Alabama at Birmingham , Birmingham, AL 35233 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9992-9597","authenticated-orcid":false,"given":"Timothy B","family":"Plante","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Vermont Larner College of Medicine , Burlington, VT 05401 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne E","family":"Judd","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Alabama at Birmingham , Birmingham, AL 35233 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2465-6739","authenticated-orcid":false,"given":"Leslie A","family":"McClure","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Biostatistics, Dornsife School of Public Health, Drexel University , Philadelphia, PA 19104 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7970-6756","authenticated-orcid":false,"given":"April P","family":"Carson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Center , Jackson, MS 39216 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7871-6143","authenticated-orcid":false,"given":"Mary","family":"Cushman","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Vermont Larner College of Medicine , Burlington, VT 05401 ,","place":["USA"]},{"name":"Department of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine , Burlington, VT 05401 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"issue":"3","key":"2025031717050265600_dgae301-B1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S2213-8587(19)30026-9","article-title":"The obesity transition: stages of the global epidemic","volume":"7","author":"Jaacks","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10027","key":"2025031717050265600_dgae301-B2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","article-title":"Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants","volume":"387","author":"NCD Risk Factor Collaboration","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"2025031717050265600_dgae301-B3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","article-title":"Global estimates of diabetes prevalence for 2013 and projections for 2035","volume":"103","author":"Guariguata","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"2025031717050265600_dgae301-B4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-018-0812-z","article-title":"The global epidemic of the metabolic syndrome","volume":"20","author":"Saklayen","year":"2018","journal-title":"Curr Hypertens Rep"},{"issue":"19","key":"2025031717050265600_dgae301-B5","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1001\/jama.2015.4260","article-title":"Prevalence of the metabolic syndrome in the United States, 2003-2012","volume":"313","author":"Aguilar","year":"2015","journal-title":"JAMA"},{"issue":"14","key":"2025031717050265600_dgae301-B6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis","volume":"56","author":"Mottillo","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"2025031717050265600_dgae301-B7","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2025031717050265600_dgae301-B8","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/jch.12785","article-title":"The clinical significance of N-terminal pro-brain natriuretic peptide in detecting the residual cardiovascular risk in hypertension and other clinical conditions and in predicting future cardiovascular events","volume":"18","author":"Chrysant","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"2025031717050265600_dgae301-B9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Levin","year":"1998","journal-title":"N Engl J Med"},{"issue":"4","key":"2025031717050265600_dgae301-B10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/01.CIR.86.4.1081","article-title":"Molecular biology of the natriuretic peptides and their receptors","volume":"86","author":"Koller","year":"1992","journal-title":"Circulation"},{"issue":"3","key":"2025031717050265600_dgae301-B11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1172\/JCI59701","article-title":"Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes","volume":"122","author":"Bordicchia","year":"2012","journal-title":"J Clin Invest"},{"issue":"12","key":"2025031717050265600_dgae301-B12","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.2337\/db09-0393","article-title":"Natriuretic peptides\/cGMP\/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity","volume":"58","author":"Miyashita","year":"2009","journal-title":"Diabetes"},{"issue":"8","key":"2025031717050265600_dgae301-B13","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1210\/en.2010-0119","article-title":"The atrial natriuretic peptide and guanylyl cyclase-a system modulates pancreatic beta-cell function","volume":"151","author":"Ropero","year":"2010","journal-title":"Endocrinology"},{"issue":"9","key":"2025031717050265600_dgae301-B14","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.2337\/db13-0478","article-title":"NH2-terminal pro\u2013brain natriuretic peptide and risk of diabetes","volume":"62","author":"Lazo","year":"2013","journal-title":"Diabetes"},{"issue":"5","key":"2025031717050265600_dgae301-B15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.diabet.2015.04.005","article-title":"Changes in N-terminal pro-B-type natriuretic peptide and incidence of diabetes: the multi-ethnic study of atherosclerosis (MESA)","volume":"41","author":"Sanchez","year":"2015","journal-title":"Diabetes Metab"},{"issue":"2","key":"2025031717050265600_dgae301-B16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5114\/aoms.2011.22075","article-title":"Relationship between N-terminal pro-B-type natriuretic peptide levels and metabolic syndrome","volume":"7","author":"Bao","year":"2011","journal-title":"Arch Med Sci"},{"issue":"4","key":"2025031717050265600_dgae301-B17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/01.HYP.0000179575.13739.72","article-title":"N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome","volume":"46","author":"Olsen","year":"2005","journal-title":"Hypertension"},{"issue":"3","key":"2025031717050265600_dgae301-B18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000086678","article-title":"The reasons for geographic and racial differences in stroke study: objectives and design","volume":"25","author":"Howard","year":"2005","journal-title":"Neuroepidemiology"},{"key":"2025031717050265600_dgae301-B19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.annepidem.2021.10.010","article-title":"Biomarkers as MEDiators of racial disparities in risk factors (BioMedioR): rationale, study design and statistical considerations","volume":"66","author":"Long","year":"2021","journal-title":"Ann Epidemiol"},{"issue":"1","key":"2025031717050265600_dgae301-B20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12874-019-0890-x","article-title":"Assembling and validating a heart failure-free cohort from the reasons for geographic and racial differences in stroke (REGARDS) study","volume":"20","author":"Goyal","year":"2020","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"2025031717050265600_dgae301-B21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1161\/CIRCULATIONAHA.115.017298","article-title":"N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity: the atherosclerosis risk in communities (ARIC) study","volume":"133","author":"Ndumele","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"2025031717050265600_dgae301-B22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jash.2010.02.001","article-title":"Prevalence of hypertension by duration and age at exposure to the stroke belt","volume":"4","author":"Howard","year":"2010","journal-title":"J Am Soc Hypertens"},{"issue":"9","key":"2025031717050265600_dgae301-B23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"6","key":"2025031717050265600_dgae301-B24","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"issue":"7","key":"2025031717050265600_dgae301-B25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"issue":"16","key":"2025031717050265600_dgae301-B26","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"2025031717050265600_dgae301-B27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-3-319-19425-7_13","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","author":"Harrell","year":"2015"},{"issue":"3","key":"2025031717050265600_dgae301-B28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1373\/clinchem.2012.194167","article-title":"Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women","volume":"59","author":"Everett","year":"2013","journal-title":"Clin Chem"},{"issue":"10","key":"2025031717050265600_dgae301-B29","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.metabol.2016.06.002","article-title":"Longitudinal assessment of N-terminal pro-B-type natriuretic peptide and risk of diabetes in older adults: the cardiovascular health study","volume":"65","author":"Brutsaert","year":"2016","journal-title":"Metab Clin Exp"},{"issue":"12","key":"2025031717050265600_dgae301-B30","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.2337\/dc20-0553","article-title":"Opposing associations of NT-proBNP with risks of diabetes and diabetes-related complications","volume":"43","author":"Birukov","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"2025031717050265600_dgae301-B31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJMcibr1204796","article-title":"The natriuretic peptides and fat metabolism","volume":"367","author":"Wang","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"2025031717050265600_dgae301-B32","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","article-title":"Cardiac natriuretic peptides","volume":"17","author":"Goetze","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"2025031717050265600_dgae301-B33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12933-017-0601-z","article-title":"NTproBNP in insulin-resistance mediated conditions: overweight\/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato Study","volume":"16","author":"Baldassarre","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"2025031717050265600_dgae301-B34","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/ajh\/hpaa224","article-title":"N-terminal Pro-B-Type natriuretic peptide and longitudinal risk of hypertension","volume":"34","author":"Nicoli","year":"2021","journal-title":"Am J Hypertens"},{"issue":"11","key":"2025031717050265600_dgae301-B35","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/CIRCULATIONAHA.106.655142","article-title":"Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals","volume":"115","author":"Wang","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"2025031717050265600_dgae301-B36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12933-021-01221-w","article-title":"Performance of the recommended ESC\/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus","volume":"20","author":"Prausm\u00fcller","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2025031717050265600_dgae301-B37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13098-022-00837-6","article-title":"NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes","volume":"14","author":"Malachias","year":"2022","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"2025031717050265600_dgae301-B38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jacbts.2023.08.011","article-title":"MANP in hypertension with metabolic syndrome: proof-of-concept study of natriuretic peptide-based therapy for cardiometabolic disease","volume":"9","author":"Ma","year":"2024","journal-title":"JACC Basic Transl Sci"},{"issue":"11","key":"2025031717050265600_dgae301-B39","doi-asserted-by":"crossref","first-page":"e029083","DOI":"10.1161\/JAHA.122.029083","article-title":"Subclinical cardiovascular disease in US adults with and without diabetes","volume":"12","author":"Fang","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"2025031717050265600_dgae301-B40","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1055\/s-0037-1616754","article-title":"Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples","volume":"86","author":"Lewis","year":"2001","journal-title":"Thromb Haemost"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae301\/57889155\/dgae301.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/4\/e1185\/57889155\/dgae301.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/4\/e1185\/57889155\/dgae301.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T17:05:22Z","timestamp":1742231122000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/4\/e1185\/7664546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,4]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5,4]]},"published-print":{"date-parts":[[2025,3,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae301","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,5,4]]}}}